Pfizer Inc. (NYSE:PFE) Announces $0.43 Quarterly Dividend

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Wednesday, June 24th. Investors of record on Friday, July 24th will be given a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 1st. This represents a c) annualized dividend and a dividend yield of 7.2%. The ex-dividend date is Friday, July 24th.

Pfizer has decreased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 16 consecutive years. Pfizer has a dividend payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Pfizer to earn $2.86 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 60.1%.

Pfizer Trading Down 2.7%

NYSE PFE opened at $24.05 on Thursday. Pfizer has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a 50 day moving average price of $26.07 and a 200 day moving average price of $26.31. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $137.07 billion, a PE ratio of 18.36 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer will post 2.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Brighton Jones LLC raised its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank increased its holdings in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its stake in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC lifted its stake in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.